196 related articles for article (PubMed ID: 35017459)
1. A Case of Metaplastic Squamous Cell Carcinoma of the Breast that Showed a Pathological Complete Response After Neoadjuvant Chemotherapy with Weekly Paclitaxel.
Noro A; Ishitobi M; Hanamura N; Kashikura Y; Yamashita M; Kozuka Y; Saito K; Mizuno T; Ogawa T
Am J Case Rep; 2022 Jan; 23():e935035. PubMed ID: 35017459
[TBL] [Abstract][Full Text] [Related]
2. [A Case of Metaplastic Squamous Cell Carcinoma of the Breast Diagnosed after Neoadjuvant Chemotherapy].
Ishikawa N; Saimura M; Koga K; Anan K; Mitsuyama S; Tamiya S
Gan To Kagaku Ryoho; 2018 Jul; 45(7):1101-1103. PubMed ID: 30042281
[TBL] [Abstract][Full Text] [Related]
3. A case of primary squamous cell carcinoma of the breast with pathologic complete response after neoadjuvant chemotherapy.
Alan O; Telli TA; Ercelep O; Hasanov R; Simsek ET; Mutis A; Ones T; Kaya H; Yumuk PF
Curr Probl Cancer; 2019 Aug; 43(4):308-311. PubMed ID: 29880396
[TBL] [Abstract][Full Text] [Related]
4. Metaplastic breast cancer with a unique presentation and complete response to chemotherapy: a case report.
Nahhat F; Doyya M; Zabad K; Ksiri H
BMC Womens Health; 2024 May; 24(1):285. PubMed ID: 38734591
[TBL] [Abstract][Full Text] [Related]
5. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
[TBL] [Abstract][Full Text] [Related]
6. [Phase II clinical trial of neoadjuvant therapy with carboplatin plus paclitaxel for locally advanced triple-negative breast cancer].
Ma WY; Zhang P; Zhang BL; Wang X; Xu XZ; Zheng S; Wang JY; Cai RG; Yuan P; Ma F; Fan Y; Xu BH
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):770-4. PubMed ID: 23291072
[TBL] [Abstract][Full Text] [Related]
7. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
[TBL] [Abstract][Full Text] [Related]
8. The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant Chemotherapy.
Flores-Balcázar CH; Castro-Alonso FJ; Hernández-Barragán TP; Delgado-de la Mora J; Daidone A; Trejo-Durán GE
Oncology (Williston Park); 2021 Mar; 35(3):139-143. PubMed ID: 33818049
[TBL] [Abstract][Full Text] [Related]
9. [Two cases of recurrent breast cancer with regional lymph node metastases showing a complete response to trastuzumab and paclitaxel treatment].
Ohsako T; Inoue K; Nagamoto N; Yoshida Y; Nakahara O
Gan To Kagaku Ryoho; 2006 Sep; 33(9):1301-3. PubMed ID: 16969029
[TBL] [Abstract][Full Text] [Related]
10. [A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywith Immediate Reconstruction Using a Tissue Expander after Nab-Paclitaxel Combined with Chemotherapy].
Nonomura A; Aomatsu N; Tei S; Haraoka G; Tsujio G; Yamakoshi Y; Wang E; Nagashima D; Hirakawa T; Iwauchi T; Nishii T; Morimoto J; Nakazawa K; Uchima Y; Takeuchi K
Gan To Kagaku Ryoho; 2016 Nov; 43(12):2056-2058. PubMed ID: 28133220
[TBL] [Abstract][Full Text] [Related]
11. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
12. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
13. Successful neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for an elderly patient with inflammatory breast cancer.
Shimizu T; Hirano A; Watanabe O; Kinoshita J; Kimura K; Kamimura M; Domoto K; Kim N; Ogawa K; Fujibayashi M
Anticancer Res; 2010 Feb; 30(2):581-5. PubMed ID: 20332474
[TBL] [Abstract][Full Text] [Related]
14. Near-complete pathological response with preoperative chemotherapy in a patient with metaplastic breast carcinoma.
Amini A; Kakkis J; Reitherman R; Ibarra J; Sanati H
Anticancer Drugs; 2013 Aug; 24(7):765-8. PubMed ID: 23719538
[TBL] [Abstract][Full Text] [Related]
15. Level III axillary lymph nodes involvement in node positive breast cancer received neoadjuvant chemotherapy.
Fan Z; Li J; Wang T; Xie Y; Fan T; Lin B; Ouyang T
Breast; 2013 Dec; 22(6):1161-5. PubMed ID: 24080493
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
18. [A case of giant advanced ulcerative breast cancer managed with epirubicin and cyclophosphamide followed by weekly paclitaxel].
Moriya T; Fukatsu K; Ueda S; Iwaya K; Osaki A; Yamamoto J
Gan To Kagaku Ryoho; 2010 May; 37(5):907-10. PubMed ID: 20495326
[TBL] [Abstract][Full Text] [Related]
19. [Chemo-Resistant Breast Carcinoma with Cartilaginous Differentiation Manifestation after Neoadjuvant Chemotherapy-A Case Report].
Konishi K; Araya J; Nagabuchi M; Sakamoto T; Takakuwa Y; Sasaki M; Watanabe K; Hirano S
Gan To Kagaku Ryoho; 2021 Jul; 48(7):951-953. PubMed ID: 34267034
[TBL] [Abstract][Full Text] [Related]
20. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
